| # | Title | Journal | Year | Citations |
|---|
| 1 | Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents | Biologics: Targets and Therapy | 2013 | 220 |
| 2 | Gut microbiota: next frontier in understanding human health and development of biotherapeutics | Biologics: Targets and Therapy | 2011 | 181 |
| 3 | The molecular profile of luminal B breast cancer | Biologics: Targets and Therapy | 2012 | 149 |
| 4 | <p>Monoclonal antibody therapy of solid tumors: clinical limitations and novel strategies to enhance treatment efficacy</p> | Biologics: Targets and Therapy | 2019 | 115 |
| 5 | A review of becaplermin gel in the treatment of diabetic neuropathic foot ulcers | Biologics: Targets and Therapy | 2008 | 111 |
| 6 | Natural killer cells: role in local tumor growth and metastasis | Biologics: Targets and Therapy | 2012 | 100 |
| 7 | Vitamins D, C, and E in the prevention of type 2 diabetes mellitus: modulation of inflammation and oxidative stress | Biologics: Targets and Therapy | 2011 | 89 |
| 8 | Biologic targeting in the treatment of inflammatory bowel diseases | Biologics: Targets and Therapy | 2009 | 88 |
| 9 | Gaucher disease: clinical profile and therapeutic developments | Biologics: Targets and Therapy | 2010 | 86 |
| 10 | Complexing proteins in botulinum toxin type A drugs: a help or a hindrance? | Biologics: Targets and Therapy | 2010 | 83 |
| 11 | Update on the use of systemic biologic agents in the treatment of noninfectious uveitis | Biologics: Targets and Therapy | 2014 | 82 |
| 12 | Cervarix: a vaccine for the prevention of HPV 16, 18-associated cervical cancer | Biologics: Targets and Therapy | 2008 | 80 |
| 13 | <p>Remicade<sup>®</sup> (infliximab): 20 years of contributions to science and medicine</p> | Biologics: Targets and Therapy | 2019 | 78 |
| 14 | The effect of erythropoietin on normal and neoplastic cells | Biologics: Targets and Therapy | 2012 | 77 |
| 15 | Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase | Biologics: Targets and Therapy | 2010 | 76 |
| 16 | Mechanism and Applications of CRISPR/Cas-9-Mediated Genome Editing | Biologics: Targets and Therapy | 2021 | 75 |
| 17 | Biological targets for isatin and its analogues: Implications for therapy | Biologics: Targets and Therapy | 2007 | 74 |
| 18 | Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib | Biologics: Targets and Therapy | 2014 | 73 |
| 19 | Botulinum toxin type A products are not interchangeable: a review of the evidence | Biologics: Targets and Therapy | 2014 | 70 |
| 20 | Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID) | Biologics: Targets and Therapy | 2009 | 70 |
| 21 | Efficacy of anti-IL-1 treatment in familial Mediterranean fever: a systematic review of the literature | Biologics: Targets and Therapy | 2016 | 66 |
| 22 | Resistant mutations in CML and Ph+ALL – role of ponatinib | Biologics: Targets and Therapy | 2014 | 65 |
| 23 | Clinical utility of asthma biomarkers: from bench to bedside | Biologics: Targets and Therapy | 2013 | 64 |
| 24 | Biologics: the role of delivery systems in improved therapy | Biologics: Targets and Therapy | 2014 | 63 |
| 25 | Cetuximab: its unique place in head and neck cancer treatment | Biologics: Targets and Therapy | 2013 | 62 |
| 26 | A combined phase I and II open label study on the effects of a seaweed extract nutrient complex on osteoarthritis | Biologics: Targets and Therapy | 2010 | 61 |
| 27 | Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency | Biologics: Targets and Therapy | 2009 | 58 |
| 28 | Duration of remission after halving of the etanercept dose in patients with ankylosing spondylitis: a randomized, prospective, long-term, follow-up study | Biologics: Targets and Therapy | 2013 | 57 |
| 29 | Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases | Biologics: Targets and Therapy | 2012 | 56 |
| 30 | Novel microtubule-targeting agents – the epothilones | Biologics: Targets and Therapy | 2008 | 55 |
| 31 | Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex | Biologics: Targets and Therapy | 2013 | 55 |
| 32 | The Current Status of Gene Therapy for the Treatment of Cancer | Biologics: Targets and Therapy | 2021 | 55 |
| 33 | Paroxysmal nocturnal hemoglobinuria: pathophysiology, natural history and treatment options in the era of biological agents | Biologics: Targets and Therapy | 2008 | 54 |
| 34 | Hepatocellular carcinoma: natural history, current management, and emerging tools | Biologics: Targets and Therapy | 2012 | 54 |
| 35 | Erlotinib in the treatment of advanced pancreatic cancer | Biologics: Targets and Therapy | 2008 | 52 |
| 36 | Clinical use of topical thrombin as a surgical hemostat | Biologics: Targets and Therapy | 2008 | 52 |
| 37 | Clinical uses of GM-CSF, a critical appraisal and update | Biologics: Targets and Therapy | 2008 | 51 |
| 38 | The role of epigenetic mechanisms and processes in autoimmune disorders | Biologics: Targets and Therapy | 2012 | 51 |
| 39 | Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70 | Biologics: Targets and Therapy | 2012 | 50 |
| 40 | Giant-cell tumor of bone: treatment options and role of denosumab | Biologics: Targets and Therapy | 2015 | 49 |
| 41 | Cervarix™: a vaccine for the prevention of HPV 16, 18-associated cervical cancer | Biologics: Targets and Therapy | 2008 | 48 |
| 42 | Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure | Biologics: Targets and Therapy | 2012 | 47 |
| 43 | First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors | Biologics: Targets and Therapy | 2012 | 46 |
| 44 | Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy | Biologics: Targets and Therapy | 2019 | 46 |
| 45 | Prevention of rotavirus gastroenteritis in infants and children: rotavirus vaccine safety, efficacy, and potential impact of vaccines | Biologics: Targets and Therapy | 2010 | 45 |
| 46 | Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors | Biologics: Targets and Therapy | 2014 | 45 |
| 47 | Therapeutic vaccines and cancer: focus on DPX-0907 | Biologics: Targets and Therapy | 2014 | 45 |
| 48 | HER2 breast cancer therapies: a review | Biologics: Targets and Therapy | 2009 | 45 |
| 49 | Review of tocilizumab in the treatment of rheumatoid arthritis | Biologics: Targets and Therapy | 2008 | 44 |
| 50 | Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants | Biologics: Targets and Therapy | 2008 | 44 |
